{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:29:48Z","timestamp":1793608188351,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006765","name":"Chinese Medical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004433","name":"Chinese Pharmaceutical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtha.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:34:25Z","timestamp":1775842465000},"page":"2461-2472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying risk factors for major bleeding in patients with atrial fibrillation using direct oral anticoagulants: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mang-Mang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Chun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-3734","authenticated-orcid":false,"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.04.001_bib1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.04.001_bib2","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.jtha.2026.04.001_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-pharmtox-032823-122811","article-title":"Oral anticoagulants beyond warfarin","volume":"64","author":"Olie","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jtha.2026.04.001_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2026.04.001_bib5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s11239-021-02416-4","article-title":"Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting","volume":"52","author":"Afzal","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.04.001_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ehjqcco\/qcaf002","article-title":"Temporal trends of prescription rates, oral anticoagulants dose, clinical outcomes and factors associated with non-anticoagulation in patients with incident atrial fibrillation","volume":"11","author":"Liao","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jtha.2026.04.001_bib7","article-title":"Real-world national trends and influencing factors preference of non-vitamin K antagonist oral anticoagulants in China","volume":"10","author":"Zhu","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2026.04.001_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2019000072","article-title":"What we have learned about direct oral anticoagulant reversal","volume":"2019","author":"Siegal","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2026.04.001_bib9","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2026.04.001_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.04.001_bib11","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1007\/s12325-020-01440-9","article-title":"Evaluation of the incremental healthcare economic burden of patients with atrial fibrillation treated with direct-acting oral anticoagulants and hospitalized for major bleeds in the USA","volume":"37","author":"Deitelzweig","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtha.2026.04.001_bib12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.04.001_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.04.001_bib14","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O'Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.04.001_bib15","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.04.001_bib16","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.5551\/jat.64842","article-title":"A novel risk score for major bleeding in Japanese patients with non-valvular atrial fibrillation: the J-RISK AF Study","volume":"31","author":"Akao","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jtha.2026.04.001_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2023.02.017","article-title":"New score for predicting major bleeding in patients with atrial fibrillation using direct oral anticoagulants","volume":"376","author":"Chen","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jtha.2026.04.001_bib18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/heartjnl-2021-319702","article-title":"Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants","volume":"108","author":"Barnett-Griness","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.jtha.2026.04.001_bib19","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"Aggarwal","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.04.001_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/europace\/euz361","article-title":"Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis","volume":"22","author":"Malik","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.jtha.2026.04.001_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/ehjcvp\/pvae097","article-title":"Risk of bleeding with the concurrent use of amiodarone and DOACs: a systematic review and meta-analysis","volume":"11","author":"Michael","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2026.04.001_bib22","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1055\/s-0043-1770100","article-title":"Risk of bleeding in liver cirrhosis receiving direct oral anticoagulants: a systematic review and meta-analysis","volume":"123","author":"Li","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.001_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2021.11.021","article-title":"Meta-analysis comparing apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation","volume":"166","author":"Mamas","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2026.04.001_bib24","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/STROKEAHA.120.031007","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients","volume":"52","author":"Zhu","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.04.001_bib25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2026.04.001_bib26","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.001_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.757087","article-title":"Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"Gao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2026.04.001_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.022","article-title":"Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: a report from a prospective European observational registry","volume":"128","author":"Mei","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jtha.2026.04.001_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007230","article-title":"Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation","volume":"14","author":"Jackevicius","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jtha.2026.04.001_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2026.04.001_bib31","article-title":"Efficacy and safety of direct oral anticoagulants with and without aspirin: a systematic review and meta-analysis","volume":"40","author":"Almas","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jtha.2026.04.001_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102827","article-title":"Aspirin use in patients with elevated lipoprotein(a): impact on cardiovascular events and bleeding","volume":"49","author":"Masson","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jtha.2026.04.001_bib33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cpt.1952","article-title":"Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: a real-life study","volume":"108","author":"Salameh","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2026.04.001_bib34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ehjcvp\/pvab004","article-title":"Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation","volume":"7","author":"Lee","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2026.04.001_bib35","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.04.001_bib36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/psp4.12347","article-title":"Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation","volume":"7","author":"Cirincione","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2026.04.001_bib37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40262-025-01474-8","article-title":"Plasma concentrations of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and different degrees of obesity","volume":"64","author":"Menichelli","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.04.001_bib38","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.3390\/jcm10184185","article-title":"Direct oral anticoagulants in patients with obesity and atrial fibrillation: position paper of Italian National Association of Hospital Cardiologists (ANMCO)","volume":"10","author":"Mocini","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.04.001_bib39","first-page":"1161","article-title":"A prediction model for nonpersistence or nonadherence to direct oral anticoagulants in hospitalized patients with atrial fibrillation","volume":"28","author":"Wirbka","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jtha.2026.04.001_bib40","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.108.824151","article-title":"Statin adherence and risk of accidents: a cautionary tale","volume":"119","author":"Dormuth","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.04.001_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.3208","article-title":"Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleeding","volume":"7","author":"Rahman","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2026.04.001_bib42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40801-021-00258-3","article-title":"Association of type of antidepressant initiation with bleeding risk in atrial fibrillation patients taking oral anticoagulants","volume":"8","author":"Shao","year":"2021","journal-title":"Drugs Real World Outcomes"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:13:11Z","timestamp":1793607191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626002175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1538783626002175"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.001","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying risk factors for major bleeding in patients with atrial fibrillation using direct oral anticoagulants: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}